- Active not recruitingPHASE2
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
This study is looking into a new medication called Nipocalimab for people with active inflammatory myopathies, a condition that causes muscle weakness and inflammation. It aims to see if Nipocalimab is safe and helps more than a dummy treatment.
For: MyositisUnited States · Canada · Czechia - Active not recruitingPHASE3
Nipocalimab in Moderate to Severe Sjogren's Disease
This study is testing a new drug called nipocalimab for people with moderate to severe Sjögren's disease. Researchers want to see if it's safe and effective compared to a dummy treatment (placebo) alongside their usual care.
For: Sjogrens SyndromeUnited States · Argentina · Austria - RecruitingPhase III
A study of nipocalimab in adults with moderate to severe systemic lupus erythematosus
This study is testing a new drug called nipocalimab for adults with moderate to severe lupus (SLE). Researchers want to see if it works better than a dummy drug to reduce symptoms. It involves regular visits and monitoring over several years.
For: Systemic lupus erythematosusUnited Kingdom · England · Argentina - RecruitingPHASE3
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
This study is looking at a new medicine called nipocalimab for adults with moderate to severe lupus. It compares nipocalimab to a dummy treatment (placebo) to see if it can help reduce inflammation and improve lupus symptoms.
For: Lupus Erythematosus, SystemicUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
This study is testing a new medicine called nipocalimab for adults with a muscle weakness condition called generalised myasthenia gravis (gMG). Researchers want to see if it's safe and helps improve symptoms compared to a dummy treatment. They are also looking at different ways to give the medicine.
For: Myasthenia GravisUnited States · Australia · Belgium - RecruitingPHASE3
A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
This study is testing a new medicine, nipocalimab, to see if it can help prevent a serious blood condition called FNAIT in babies. FNAIT can cause low platelet counts in newborns, which can lead to bleeding problems. Researchers want to know if nipocalimab is effective and safe.
For: Thrombocytopenia, Neonatal AlloimmuneBelgium · Brazil · France - RecruitingPHASE3
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
This study looks at a new medicine called nipocalimab to help pregnant people whose babies are at risk of a serious blood condition called HDFN. It aims to see if the medicine can stop the baby from developing anaemia while still in the womb.
For: Hemolytic Disease of the Fetus and NewbornUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
This study is looking at new ways to prevent a serious bleeding condition in babies called FNAIT. It compares a new medicine, nipocalimab, with standard treatments like IVIG, in pregnant women who have had FNAIT before. The aim is to find safer, more effective ways to protect newborns.
For: Thrombocytopenia, Neonatal AlloimmuneUnited States · Austria · Germany - RecruitingPHASE2, PHASE3
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine called nipocalimab for adults with a nerve condition called CIDP. It wants to see if nipocalimab is safe and effective at stopping CIDP symptoms from returning, compared to a dummy medicine, after patients have improved on nipocalimab first.
For: Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingUnited States · Argentina · Australia